2abj

From Proteopedia

Revision as of 18:42, 12 November 2007 by OCA (Talk | contribs)
(diff) ←Older revision | Current revision (diff) | Newer revision→ (diff)
Jump to: navigation, search

2abj, resolution 2.200Å

Drag the structure with the mouse to rotate

Crystal structure of human branched chain amino acid transaminase in a complex with an inhibitor, C16H10N2O4F3SCl, and pyridoxal 5' phosphate.

Contents

Overview

The inhibition of the cytosolic isoenzyme BCAT that is expressed, specifically in neuronal tissue is likely to be useful for the treatment, of neurodegenerative and other neurological disorders where glutamatergic, mechanisms are implicated. Compound 2 exhibited an IC50 of 0.8 microM in, the hBCATc assays; it is an active and selective inhibitor. Inhibitor 2, also blocked calcium influx into neuronal cells following inhibition of, glutamate uptake, and demonstrated neuroprotective efficacy in vivo. SAR, pharmacology, and the crystal structure of hBCATc with inhibitor 2 are, described.

Disease

Known diseases associated with this structure: Hyperleucinemia-isoleucinemia or hypervalinemia (1) OMIM:[113520]

About this Structure

2ABJ is a Single protein structure of sequence from Homo sapiens with CBC and PLP as ligands. Active as Branched-chain-amino-acid transaminase, with EC number 2.6.1.42 Full crystallographic information is available from OCA.

Reference

The design and synthesis of human branched-chain amino acid aminotransferase inhibitors for treatment of neurodegenerative diseases., Hu LY, Boxer PA, Kesten SR, Lei HJ, Wustrow DJ, Moreland DW, Zhang L, Ahn K, Ryder TR, Liu X, Rubin JR, Fahnoe K, Carroll RT, Dutta S, Fahnoe DC, Probert AW, Roof RL, Rafferty MF, Kostlan CR, Scholten JD, Hood M, Ren XD, Schielke GP, Su TZ, Taylor CP, Mistry A, McConnell P, Hasemann C, Ohren J, Bioorg Med Chem Lett. 2006 May 1;16(9):2337-40. Epub 2005 Sep 6. PMID:16143519

Page seeded by OCA on Mon Nov 12 20:48:30 2007

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools